Defeating Alzheimer's disease and other dementias: a priority for European science and society

B Winblad, P Amouyel, S Andrieu, C Ballard… - The Lancet …, 2016 - thelancet.com
Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …

Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal

L Fratiglioni, C Qiu - The Lancet Neurology, 2011 - thelancet.com
Less than two decades have passed since the first incidence data for Alzheimer's disease
(AD) and other dementias were reported, during which there have been many achievements …

A resurrection of aducanumab for Alzheimer's disease

L Schneider - The Lancet Neurology, 2020 - thelancet.com
In Context estimated as about+ 1· 5 in ENGAGE and+ 1· 75 in EMERGE. Using the
percentage differences relative to placebo (ie,–2% and+ 23%), the mean difference between …

Advances in Alzheimer's disease research over the past two decades

CR Jack - The Lancet Neurology, 2022 - thelancet.com
Over the past two decades, the landscape of dementia research has changed drastically
due to advances in knowledge at the molecular, cellular, animal, and human levels …

Research priorities to reduce the global burden of dementia by 2025

H Shah, E Albanese, C Duggan, I Rudan… - The Lancet …, 2016 - thelancet.com
Summary At the First WHO Ministerial Conference on Global Action Against Dementia in
March, 2015, 160 delegates, including representatives from 80 WHO Member States and …

Why do so many clinical trials of therapies for Alzheimer's disease fail?

RM Anderson, C Hadjichrysanthou, S Evans… - The Lancet, 2017 - thelancet.com
Alzheimer's disease is an irreversible, progressive brain disorder that accounts for about 50–
75% of all cases of dementia. 1 Alzheimer's disease is characterised by the presence of …

Sex differences in Alzheimer's disease and other dementias

CM Mazure, J Swendsen - The Lancet Neurology, 2016 - thelancet.com
The Lancet Neurology Commission1 draws attention to the dramatically increasing
personal, societal, and economic costs of Alzheimer's disease (AD) and associated …

The age gap between patients in clinical studies and in the general population: a pitfall for dementia research

N Schoenmaker, WA Van Gool - The Lancet Neurology, 2004 - thelancet.com
Summary The growing global disease burden attributable to dementia has strongly
stimulated research activities. However, patients with dementia that are included in clinical …

Dementia prevention, intervention, and care

G Livingston, A Sommerlad, V Orgeta, SG Costafreda… - The lancet, 2017 - thelancet.com
Executive summary Acting now on dementia prevention, intervention, and care will vastly
improve living and dying for individuals with dementia and their families, and in doing so …

Alzheimer's disease

P Scheltens, K Blennow, MMB Breteler, B De Strooper… - The Lancet, 2016 - thelancet.com
Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …